To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.

Phase 3

Completed

• Conditions: Neuropathic Pain

• Registration Number: NCT00141375
• Lead Sponsor: Pfizer

Brief Summary

To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-08
• Study First Submitted: 2005-08-30
• Study First Submitted QC: 2005-08-31
• Study First Posted: 2005-09-01
• Study Completion: 2006-01
• Status Verified: 2008-01
• Last Update Submitted: 2008-01-09
• Last Update Posted: 2008-01-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 132

Inclusion Criteria

• Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury.
• Must have received study medication under double-blind conditions.

Exclusion Criteria

• Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety and Efficacy

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇦🇺 NSW, Australia